(SeaPRwire) – TOKYO, April 24, 2026 — In recognition of DNA DAY™, A.D.A.M. Innovations Co. (operating in Japan as Genesis Healthcare Co.) has announced a significant update to its GeneLife GeneAI Forecast service. The platform now features 15 AI-driven risk prediction models and offers improved integration with real-world lifestyle data.
The Foundation of DNA Data
GeneAI Forecast utilizes genetic data and primary biomarkers to establish a unique health and wellness baseline for every user. Using this foundation, artificial intelligence continuously improves risk assessments, moving away from static reporting toward a dynamic system that provides earlier and more precise insights into health risks.
Broadening Predictive Capabilities
The latest update adds four new prediction models: Irritable Bowel Syndrome (IBS), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Osteoarthritis, and Osteoporosis.
These conditions often progress gradually without showing early symptoms. With a total of 15 models, GeneAI Forecast offers insights that facilitate an earlier understanding of potential health risks, allowing for more effective preventive measures.
Merging Biological and Behavioral Data
GeneAI Forecast already incorporates various biomarkers, such as BMI, blood pressure, and glucose levels, to provide necessary context for DNA data. With this enhancement, the platform further improves its functionality by integrating real-world behavioral data through Apple Health and Google Fit, allowing daily activities like step counts to be factored directly into the predictive models.
By synthesizing genetic data, biological markers, and lifestyle inputs, GeneAI Forecast delivers a constantly evolving perspective on an individual’s health risks over time.
Translating Predictions into Action
By merging genetic, biological, and behavioral signals, GeneAI Forecast offers deeper insights into the factors influencing individual risk profiles. This methodology helps identify potential areas for intervention, empowering users to make more informed and proactive health decisions.
A Proactive Approach to Health
“Everything begins with DNA data—it serves as the essential foundation for understanding personal health and wellness,” stated Michel Mommejat, President of A.D.A.M. Innovations Co. “GeneAI Forecast enhances that foundation by combining genetic insights with biological markers and real-world behavior. This allows us to provide more accurate and contextualized predictions while helping individuals find practical ways to manage their risks. It is a significant move toward a more proactive and personalized model of preventive healthcare.”
With over 2.9 million genetic tests completed, A.D.A.M. Innovations continues to develop one of the most extensive genomic datasets in Japan and Asia. GeneAI Forecast represents a transition from static insights to continuous, contextual intelligence, fostering a more proactive approach to long-term health.
About A.D.A.M. Innovations Co.
Established in 2004 in Tokyo, A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.) is a leader in genomics, AI, and precision health solutions. The company creates advanced technologies ranging from clinical diagnostics to AI-driven R&D data platforms and consumer genomics. To date, A.D.A.M. Innovations has performed more than 2.9 million genetic tests and maintains the largest R&D genomic database of the Japanese population.
About GeneLife
GeneLife is the consumer genomics brand of A.D.A.M. Innovations. GeneLife provides genetic testing services directly to consumers through at-home kits and e-commerce platforms, offering personalized health and wellness insights to support better living and longevity.
About GeneAI Forecast
GeneAI Forecast is an AI-powered genomic service that enables individuals to evaluate their personalized disease risks. Covering a variety of lifestyle-related risks, chronic and progressive conditions, and cancer risks, GeneAI Forecast includes a total of 15 conditions available under the Genesis CONNECT and WGS CONNECT subscription plans, such as:
Lifestyle related risks:
- Hypertension
- Type 2 Diabetes
- Myocardial infarction
- Stroke
- Chronic kidney disease
Chronic diseases:
- Irritable Bowel Syndrome (IBS) (new)
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (new)
Progressive diseases:
- Osteoarthritis (new)
- Osteoporosis (new)
Cancer risks:
- Lung cancer
- Stomach cancer
- Colorectal cancer
- Pancreatic cancer
- Breast cancer (female-specific)
- Prostate cancer (male-specific)
GeneLife, GeneAI Forecast, and DNA DAY are registered trademarks of A.D.A.M. Innovations Co.
Apple Health is a trademark of Apple Inc. Google Fit is a trademark of Google LLC.
For more information, visit www.adam-innovations.com
Corporate media contact:
Email: press@adam-innovations.com
Media Relations:
Crocker Coulson
Email: Crocker.Coulson@aumadvisors.com
+1 (646) 652-7185
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.